Meta-Analysis as Topic Prevalence Risk Factors Prostatic Hyperplasia

Administration Oral Fibrinolytic Agents/*administration & dosage Humans Lasers Solid-State Male Prostatic Hyperplasia Risk Factors Antithrombotic Benign prostate hyperplasia (BPH) Holmium laser enucleation of the prostate (HoLEP) Perioperative safety

Disease Progression Humans Lower Urinary Tract Symptoms/etiology Male Prostatic Hyperplasia/complications/*drug therapy Risk Factors Time Factors Treatment Outcome Benign prostatic hyperplasia Early treatment Luts Outcomes complications Pharmacological treatment Prostate Surgery

*Alleles Ethnicity/genetics *Genetic Association Studies *Genetic Predisposition to Disease Genotype Humans Male Odds Ratio *Polymorphism Single Nucleotide Prostate-Specific Antigen/*genetics Prostatic Hyperplasia/*genetics Publication Bias Risk Factors Bph Psa meta-analysis polymorphism

Aged Causality Comorbidity Embolization Therapeutic/*statistics & numerical data Follow-Up Studies Humans Longitudinal Studies Lower Urinary Tract Symptoms/*epidemiology/*prevention & control Male Middle Aged Prostate/blood supply Prostatic Hyperplasia/diagnostic imaging/*epidemiology/*therapy Risk Factors Treatment Outcome

*Arteries Embolization Therapeutic Humans Lower Urinary Tract Symptoms/etiology Male Prostate/*blood supply Prostatic Hyperplasia/complications/diagnosis/*therapy Quality of Life Risk Factors Time Factors Treatment Outcome

Adult Humans Lower Urinary Tract Symptoms/*etiology Male Metabolic Syndrome Prostatic Hyperplasia Risk Factors Age Luts benign prostatic enlargement insulin resistance metabolic syndrome non-alcholic fatty liver disease prostate testosterone

Aged Aged 80 and over Case-Control Studies Chromosomes Human Pair 17/*genetics *Genetic Association Studies *Genetic Predisposition to Disease Humans Male Middle Aged Polymorphism Single Nucleotide/*genetics Prostatic Hyperplasia/genetics Prostatic Neoplasms/*genetics/pathology Risk Factors Serbia 17q12 association study meta-analysis prostate cancer single nucleotide polymorphism (SNP)

Brachytherapy Constriction Pathologic/complications/etiology Humans Laser Therapy Male Prostatic Hyperplasia/therapy Prostatic Neoplasms/*radiotherapy Radiation Injuries/etiology Radiotherapy Adjuvant/*adverse effects/methods Risk Factors Severity of Illness Index Time Factors Transurethral Resection of Prostate/*adverse effects Urethra/*injuries/pathology/*radiation effects Urination Disorders/*etiology/prevention & control Urogenital System/injuries/radiation effects

Aged *Genetic Association Studies Genetic Predisposition to Disease/*epidemiology Humans Lower Urinary Tract Symptoms/epidemiology/*genetics/physiopathology Male Middle Aged Prevalence Prostatic Hyperplasia/epidemiology/*genetics/physiopathology Risk Factors Sensitivity and Specificity Severity of Illness Index Bph Benign prostatic hyperplasia Genetics Genomics Incontinence male Luts Lower urinary tract symptoms Overactive bladder

Adrenergic alpha-Agonists Drug Therapy Combination Humans Lower Urinary Tract Symptoms/*drug therapy Male Muscarinic Antagonists Prostatic Hyperplasia/complications Randomized Controlled Trials as Topic Risk Factors Treatment Outcome

3-Oxo-5-alpha-Steroid 4-Dehydrogenase/*genetics/metabolism Androgens/metabolism Genetic Association Studies Genetic Markers Genetic Predisposition to Disease Humans Male *Polymorphism Genetic Prostatic Hyperplasia/enzymology/epidemiology/genetics Prostatic Neoplasms/enzymology/*epidemiology/genetics Risk Assessment Risk Factors

*Alcohol Drinking Humans Male Prostatic Hyperplasia/*epidemiology/prevention & control Prostatism/*epidemiology/prevention & control Risk Factors

Evidence-Based Medicine Humans Length of Stay Male Patient Selection Prostatic Hyperplasia Randomized Controlled Trials as Topic Risk Assessment Risk Factors Therapeutic Irrigation Transurethral Resection of Prostate Treatment Outcome Urinary Catheterization

Adrenergic alpha-Antagonists/*adverse effects Aged Humans Male Middle Aged Prognosis Prostatic Hyperplasia/*drug therapy Randomized Controlled Trials as Topic Risk Assessment Risk Factors Vascular Diseases/*chemically induced Vasodilation/drug effects